

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6512819

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
GRAHAM BEATON	01/20/2021
STANTON F. MCHARDY	01/15/2021
AMBROSIO LOPEZ	01/18/2021
BISMARCK CAMPOS	01/15/2021
HUA-YU LEO WANG	01/15/2021
RECEIVING PARTY DATA	
Name:	CURTANA PHARMACEUTICALS, INC.
Street Address:	4200 MARATHON BLVD.
Internal Address:	SUITE 200
City:	AUSTIN
State/Country:	TEXAS
Postal Code:	78756
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16976147
CORRESPONDENCE DATA	
Fax Number:	(650)493-6811
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	8583502300
Email:	knelson@wsgr.com, patentdocket@wsgr.com
Correspondent Name:	WILSON SONSINI GOODRICH & ROSATI
Address Line 1:	650 PAGE MILL ROAD
Address Line 4:	PALO ALTO, CALIFORNIA 94304
ATTORNEY DOCKET NUMBER:	44903-710.831
NAME OF SUBMITTER:	KATE NELSON
SIGNATURE:	/Kate Nelson/
DATE SIGNED:	01/25/2021
Total Attachments: 6	

source=Curtana 44903-710.831 Assignment to file#page1.tif
source=Curtana 44903-710.831 Assignment to file#page2.tif
source=Curtana 44903-710.831 Assignment to file#page3.tif
source=Curtana 44903-710.831 Assignment to file#page4.tif
source=Curtana 44903-710.831 Assignment to file#page5.tif
source=Curtana 44903-710.831 Assignment to file#page6.tif

PATENT ASSIGNMENT	Docket Number 44903-710.831
--------------------------	-----------------------------

The undersigned:

1. Graham BEATON San Diego, CA (US)	2. Stanton F. McHARDY Waring, TX (US)	3. Ambrosio LOPEZ San Antonio, TX (US)	4. Bismarck CAMPOS San Antonio, TX (US)
--	--	---	--

5. Hua-Yu Leo WANG
San Antonio, TX (US)

(the "Inventor(s)"), desire to assign the entire right, title and interest in and to the Inventions and Assigned Patents (each, as defined below) to Curtana Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Delaware, having a place of business at 4200 Marathon Blvd., Suite 200, Austin, TX 78756, (the "Assignee"), and Assignee desires to acquire such right, title and interest, all on the terms and conditions set forth in this Patent Assignment.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) have invented certain new and useful inventions and improvements disclosed in the following patent(s) and patent application(s):

INHIBITION OF OLIG2 ACTIVITY

- for which application serial number 16/976,147, a U.S. National Phase of PCT/US2019/020016, filed on February 28, 2019, in the U.S. Receiving Office of the Patent Cooperation Treaty, was filed with the U.S. Patent and Trademark Office on August 27, 2020.

(the "Listed Patent(s)"). As used herein: "Assigned Patents" means (a) the Listed Patent(s), (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b), (d) each and every Patent granting, issuing or reissuing from any of the foregoing under subclauses (a)-(c), (e) each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(d), and (f) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(c). "Patents" means (i) patents, certifications of inventions, inventor's certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise).

2. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents, (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (the "Inventions") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patents.

3. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Assigned Patents; (c) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.


4. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

5. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

6. Said Inventor(s) hereby request that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

7. This instrument will be interpreted and construed in accordance with the laws of the State of Delaware, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:





PATENT ASSIGNMENT		Docket Number 44903-710.831
Date: <u>1/20/21</u>	 Graham BEATON	
Date: _____	Stanton F. McHARDY	
Date: _____	Ambrosio LOPEZ	
Date: _____	Bizmarck CAMPOS	
Date: _____	Hua-Yu Leo WANG	
RECEIVED AND AGREED TO BY ASSIGNEE: Curtana Pharmaceuticals, Inc.		
Date: _____	Signature: _____ Name: Gregory Stein, MD, MBA Title: President and Chief Executive Officer	

PATENT ASSIGNMENT

Docket Number 44903-710.831

Date: _____

Graham BEATON


Date: 1/15/2021
Stephen F. McHARRYDate: 01/18/2021
Ambrosio LOPEZDate: 01/15/2021
Bismarck CAMPOSDate: 01/15/2021
Hua Fu Leo WANGRECEIVED AND AGREED TO BY ASSIGNEE: **Cartana Pharmaceuticals, Inc.**

Date: _____

Signature: _____

Name: Gregory Stein, MD, MBA

Title: President and Chief Executive Officer

PATENT ASSIGNMENT		Docket Number 44903-710.831
Date:	Graham BEATON	
Date:	Stanton F. McHARDY	
Date:	Ambrosio LOPEZ	
Date:	Bismarck CAMPOS	
Date:	Hua-Yu Leo WANG	
RECEIVED AND AGREED TO BY ASSIGNEE: Curtana Pharmaceuticals, Inc.		
Date: <u>1/25/21</u>	Signature: 	
	Name: Gregory Stein, MD, MBA	
	Title: President and Chief Executive Officer	

PATENT ASSIGNMENT

Docket Number 44903-710.831

The undersigned:

- | | | | |
|--|--|---|--|
| 1. Graham BEATON
San Diego, CA (US) | 2. Stanton F. McHARDY
Waring, TX (US) | 3. Ambrosio LOPEZ
San Antonio, TX (US) | 4. Bismarck CAMPOS
San Antonio, TX (US) |
| 5. Hua-Yu Leo WANG
San Antonio, TX (US) | | | |

(the "Inventor(s)"), desire to assign the entire right, title and interest in and to the Inventions and Assigned Patents (each, as defined below) to Curtana Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Delaware, having a place of business at 4200 Marathon Blvd., Suite 200, Austin, TX 78756, (the "Assignee"), and Assignee desires to acquire such right, title and interest, all on the terms and conditions set forth in this Patent Assignment.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) have invented certain new and useful inventions and improvements disclosed in the following patent(s) and patent application(s):

INHIBITION OF OLIG2 ACTIVITY

- for which application serial number 16/976,147, a U.S. National Phase of PCT/US2019/020016, filed on February 28, 2019, in the U.S. Receiving Office of the Patent Cooperation Treaty, was filed with the U.S. Patent and Trademark Office on August 27, 2020.

(the "Listed Patent(s)"). As used herein: "Assigned Patents" means (a) the Listed Patent(s), (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b), (d) each and every Patent granting, issuing or reissuing from any of the foregoing under subclauses (a)-(c), (e) each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(d), and (f) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(e). "Patents" means (i) patents, certifications of inventions, inventor's certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise).

2. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents; (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (the "Inventions") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patents.

3. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Assigned Patents; (c) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, , cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

4. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

5. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

6. Said Inventor(s) hereby request that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

7. This instrument will be interpreted and construed in accordance with the laws of the State of Delaware, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

PATENT ASSIGNMENT	Docket Number 44903-710.831
<p>Date: _____ <u>Graham BEATON</u></p>	
<p>Date: _____ <u>Stanton F. McHARDY</u></p>	
<p>Date: _____ <u>Ambrosio LOPEZ</u></p>	
<p>Date: _____ <u>Bismarck CAMPOS</u></p>	
<p>Date: _____ <u>Hua-Yu Leo WANG</u></p>	
<p>RECEIVED AND AGREED TO BY ASSIGNEE: Curtana Pharmaceuticals, Inc.</p> <p>Date: _____ Signature: _____</p> <p style="margin-left: 150px;">Name: <u>Gregory Stein, MD, MBA</u></p> <p style="margin-left: 150px;">Title: <u>President and Chief Executive Officer</u></p>	